Invest with us
Invest with us in New S-Pharma mRNA vaccine and Smart medicines R&D factory and become Shareholder - Pre IPO Investment - NOT ONLY COVID VACCINE
- S-Pharma - Investment in Biopharmaceutical R&D factory for vaccine and medicines.
- Discovering, developing and providing different branche of vaccines and medicines.
- Location of Investment: East Europe. European Union (EU)
- Production Plan: over 200 million vaccines/month (2.4 billion vaccines yearly)
- Investment in cooperation with Grafin Invest
- Investment process for S-Pharma London in cooperation and supervises with Grafin Invest Project.
S-Pharma New Vaccine R&D Factory - become shareholder
Introducing Our State-of-the-Art Biopharmaceutical R&D FacilityWe are thrilled to unveil our cutting-edge biopharmaceutical R&D factory, set to revolutionize the development of mRNA vaccines and advanced medicines. Our brand new facility is dedicated to pioneering research and development in the field of biopharmaceuticals, with a focus on innovative mRNA vaccines and smart medicines.Business Overview:
- Type of Business: Advanced Biopharmaceutical R&D specializing in mRNA vaccine development and intelligent medicine solutions.
- Development Timeline: Scheduled for completion between Q4 2022 and Q2 2023.
- Location: European Union (EU), strategically positioned to leverage a robust pharmaceutical ecosystem.
- Total Capital Investment: €640,000,000 allocated for the establishment of a world-class R&D factory for vaccines and medicines.
- Equity Structure: 640 shares, each valued at €1,000,000.
- Minimum Investment: €10,000,000 for 10 shares, each granting 10 voting rights.
- Maximum Investment: €279,000,000 for 279 shares.
- Voting Rights: Each share carries one voting right.
- Income Potential: Shares in the vaccine factory offer additional income opportunities and the potential for capital appreciation. Investors have the option to sell shares at a higher price, realizing significant returns.
- Growth Projections: Our project is poised for substantial growth, with an anticipated annual return of up to 24% over the next five years.
- Management Team: Led by an internationally renowned management team with a proven track record of success in the biopharmaceutical industry.
- Current Ownership and Investment OpportunitiesOwnership Breakdown:
- S-Pharma U.K.: 160 shares (25% ownership)
- Live Insurance Company U.K.: 64 shares
- Pharmaceutical Company: 30 shares
- Pharmaceutical Company 2: 10 shares
- Investment Funds (from USA and EU): 40 shares
- Investment Bank: 29 shares
- Private Investor: 28 shares (Investors from a diverse range of countries including Switzerland, UK, USA, Russia, Germany, UAE, Saudi Arabia, China, Italy, Bahrain, Poland, Kuwait, Croatia, Spain, Israel, Netherlands, Sweden, Norway, Denmark, and Iceland)
- Shares Available for New Investors: 279 shares
- Note: Each share includes one voting right.
- Investor Documentation: Each investor will receive a "Memorandum and Articles of Association" and a shareholder certification.
- Project Number: 888 048
- Investment Oversight: The investment process is managed and supervised by S-Pharma London in collaboration with Grafin Invest.
Project documentation for investors:
- Complete Project Documentation for Biopharmaceutical R&D FacilityWe are pleased to present the comprehensive documentation for our state-of-the-art Biopharmaceutical R&D facility, dedicated to mRNA vaccines and smart medicines. The project encompasses various critical aspects, ensuring thorough planning, execution, and oversight.
Project Documentation Overview- Financial Analysis
- Detailed breakdown of projected costs, revenues, and return on investment (ROI).
- Comprehensive financial models, including profit and loss statements, cash flow forecasts, and balance sheets.
- Feasibility Study
- Evaluation of market demand, competitive landscape, and potential risks.
- Analysis of regulatory requirements, economic factors, and technical viability.
- Technical Calculation
- In-depth technical specifications and performance metrics for facility operations.
- Calculations related to capacity, efficiency, and production capabilities.
- Designing
- Architectural and engineering designs for the R&D facility, including layout plans, safety features, and compliance with industry standards.
- Detailed blueprints for laboratory spaces, production areas, and support infrastructure.
- Supervision
- Oversight strategies for construction and development phases, ensuring adherence to design and quality standards.
- Plans for ongoing monitoring and quality assurance throughout the project lifecycle.
- Installation
- Detailed procedures for the installation of equipment and technology required for mRNA vaccine and smart medicine production.
- Coordination of logistics, testing, and operational setup.
- Miscellaneous
- Additional documentation covering project management practices, legal considerations, and stakeholder engagement.
- Contingency plans and risk management strategies.
- Support Structure
- Framework for operational support, including maintenance plans and staffing requirements.
- Outline of support services for ongoing facility operations.
- Specification
- Comprehensive specifications for all components of the R&D facility, from machinery and equipment to materials and safety protocols.
Investment and Documentation Fee- Complete Project Documentation Cost: €2,000,000
- This fee covers all aspects of the project documentation, ensuring a thorough and well-managed development process.
- Refund Policy:
- If you purchase a share in the project, the cost of the project documentation will be reimbursed to you.
- Financial Analysis
Invest with us
- Production Plan: 200 million vaccines/month (2.4 billion vaccines yearly)
- Location of Investment: European Union (EU)
Why Invest with us?
S-Pharma, a United Kingdom company for the manufacturing and sale of pharmaceutical products. Fully operational Pharmaceutical Production Facilities with all standards/certificates. Our project report also maintains that will grow by over next five years with Up to 24% return pro year.
S-Pharma - Investment in New Advanced Research and Development (SARD) Biopharmaceutical factory, for vaccine and medicines. and S-Pharma entered a public-private partnership to establish our Center for Innovation in Advanced Development and Manufacturing.
Discovering, developing and providing different branche of medicines and vaccines. The SARD facilitates advanced development of chemical, biological, radiological, and nuclear (CBRN) medical countermeasures and ensures domestic manufacturing surge capacity.
S-Pharma Inc. are member of Sentange Group London U.K.
- Vaccines are one of the greatest public health success stories in history.
- S-Pharma and its legacy companies and our partners have been working to discover and develop vaccines. Our vaccines have helped prevent a number of diseases, including ones never thought preventable. Today, we remain dedicated to the complex business of researching and producing vaccines.
- Now S-Pharma and our partners have been working to discover and develop coronavirus vaccines.
- BCG Vaccine
- VARICELLA VACCINE
- MMR VACCINE
- DTP VACCINE
- INFLUENCA VACCINE
- PNEUMO VACCINE
- ROTA VACCINE
- EVAC (Ebola Vaccine)
- CORONAVIRUS COVID19 VACCINE
MEDICINES:
Consumer & Prescription medicine
- CHC – Consumer Healthcare
- Rx – Prescription medicine
Invest with us
Invest in new Biopharmaceutical R&D (research & development) factory with vaccine and medicines factory. Investment process for S-Pharma London controls and supervises Grafin Invest Project